Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cryoport, Inc. (CYRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Cryoport submits annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits such as earnings press releases. These documents outline its temperature-controlled supply chain business for the life sciences, its segment structure, risk factors, and detailed financial results.
For example, a recent Form 8-K filing reported the release of Cryoport’s financial results for a completed quarter, attaching the related press release as an exhibit. Such current reports typically summarize revenue from continuing operations, contributions from Life Sciences Services and Life Sciences Products, gross margins, operating expenses, and other key metrics. They may also describe items such as impairment charges, discontinued operations, and the impact of strategic transactions.
On this page, users can review filings that discuss Cryoport’s support for clinical and commercial cell and gene therapies, its global operations across the Americas, EMEA, and APAC, and its capital allocation activities, including share repurchase programs. Forms 10-K and 10-Q provide more extensive narrative on the company’s integrated supply chain platform, including biologistics, biostorage, bioservices, cryogenic systems, and related offerings.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy reports, helping readers quickly understand segment performance, material events, and changes in guidance. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and other filings appear promptly, while insider transaction reports on Form 4 and proxy materials, when available, can be used to analyze executive and director activity and governance matters.
Cryoport (CYRX) filed a routine Form 4 detailing insider activity by President & CEO Jerrell Shelton. On 06/24/2025 he exercised 16,344 options at $5 and immediately sold the same number of shares at a weighted-average $7.06, generating roughly $115 k in gross proceeds. On 06/25/2025 he exercised an additional 25,000 options without selling. Post-transaction ownership stands at ~937,000 shares. The sale represents less than 2% of his holdings and was executed under a pre-established 10b5-1 plan, indicating no material shift in insider sentiment.
CryoPort (NASDAQ:CYRX) filed a Form 4 reporting insider activity by director Ramkumar Mandalam on 24 Jun 2025.
The director exercised 20,000 options at $3.07, then sold 13,321 shares at a weighted-average price of $7.015. Net effect is a 6,679-share increase, lifting direct ownership 10% to 73,056 shares. Remaining derivative holdings total 60,000 options.
The open-market sale represents about 18% of his post-transaction stake and generated roughly $93k in proceeds. All trades were executed under a Rule 10b5-1 plan adopted 10 Jun 2025.
No other executives were involved and no strategic disclosures accompanied the filing.
CryoPort, Inc. (CYRX) – Form 144 Filing Overview
An insider, identified in the filing as Ramkumar Mandalam, has filed a Form 144 indicating his intent to sell 13,321 common shares of CryoPort through broker Morgan Stanley Smith Barney on or about 24 June 2025. Based on the stated aggregate market value of $87,385.76, the planned transaction equates to an implied price of roughly $6.56 per share.
The filing also discloses that Mandalam has already disposed of 16,334 shares in four separate transactions between 9 June 2025 and 13 June 2025, generating gross proceeds of $115,000 +. Combining past and proposed sales, total recent dispositions amount to 29,655 shares.
Relative to CryoPort’s 50.14 million shares outstanding, the proposed sale represents approximately 0.03 % of total shares, and the cumulative three-month sales represent about 0.06 %, suggesting limited dilution risk. The shares to be sold were acquired via a same-day stock-option exercise paid in cash. No adverse, non-public information is asserted by the filer, as required under Rule 144.
For investors, Form 144 signals potential insider sentiment changes, but the modest size versus the share count indicates a low direct share-supply impact. Nevertheless, repeated sales within a short window may warrant monitoring for future filings.
Jerrell Shelton, President, CEO, and Director of Cryoport (CYRX), executed significant stock option exercises and sales between June 17-20, 2025, as part of a pre-planned trading arrangement.
Key transactions include:
- Exercised options for 389,720 total shares at $5.00 strike price
- Sold 339,720 shares at weighted average prices between $6.33-$6.97
- Retained 50,000 shares from initial exercise
- Maintained beneficial ownership of 912,419 shares post-transactions
The transactions were conducted under a Rule 10b5-1 trading plan established on June 3, 2025. The exercised options were originally granted in August 2015 with a 48-month vesting schedule. After all transactions, Shelton continues to hold 166,344 unexercised stock options with an August 2025 expiration date.